Story
Biotechnology Firm Scribe Therapeutics Files for Nasdaq IPO
Summary
Scribe Therapeutics has submitted a registration statement for an initial public offering on the Nasdaq Global Market, planning to trade under the ticker symbol 'SCTX'.
Scribe Therapeutics, a biotechnology company, has officially filed for an initial public offering (IPO) with U.S. regulators. The company plans to list its common stock on the Nasdaq Global Market under the proposed ticker symbol SCTX.
Filing Details
According to the registration statement, Scribe Therapeutics has not yet determined the number of shares to be offered or the potential price range for the offering. The filing included placeholder values for these figures, a common practice in preliminary IPO documents.
Currently, there is no public market for Scribe's stock. The successful completion of the IPO is contingent upon the company meeting all of Nasdaq's official listing requirements.
AdKey Players and Context
A consortium of prominent financial institutions are serving as underwriters for the proposed offering. The group includes Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities.
This filing marks the first formal step in the company's journey to becoming publicly traded. For investors, the next key development will be an amended filing that discloses the specific terms of the offering, including the share count and price, which will establish the company's initial market valuation.